Artiva remains on track to share initial clinical response data and conduct U.S. Food and Drug Administration (FDA) ...
FDA Alignment -- BioAtla ( BCAB 4.08%) achieved FDA alignment on phase three trial design, dosing, comparator, and endpoints ...
We might finally be able to spot osteoarthritis early… and bring it to a halt. First, we need to agree on what it actually is ...
Texas A&M scientists have unlocked new potential for astatine-211, a rare and short-lived element, as a highly precise cancer-fighting isotope. Its alpha emissions destroy tumor cells while sparing ...
Recent research has investigated the potential health benefits of vitamin D, and the role it may play in protecting against certain health conditions. One study found that vitamin ...
To make the therapy safer and more adaptable, UChicago researchers developed a new “split” system called GA1CAR. This uses ...
Study Finds on MSN
Scientists Create ‘Molecular Crowbar’ Drug That Physically Destroys Pancreatic Cancer Protein
Scientists developed a drug that destroys a cancer protein rather than blocking it, cutting pancreatic tumor growth by half ...
Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary ...
The initial public offering (IPO) of Emmvee Photovoltaic Power Ltd, a leading manufacturer of solar photovoltaic (PV) modules ...
Continued advancement toward Phase 2/3 clinical trial initiation, on track for the first half of 2026 New preclinical data demonstrated SIL204's exceptional efficacy across multiple human cancer cell ...
Allogene Therapeutics, Inc. downgraded to Hold after ALPHA3 trial setbacks. Review updated pipeline prospects and risks.
While presenting this year’s Nobel Prize in Physiology or Medicine to three immunologists who discovered and characterized regulatory T cells, committee chair Olle Kämpe, M.D., Ph.D., told the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback